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ABSTRACT 
 
 
 Pediatric high-grade gliomas (pHGGs), with a two-year survival rate of less than 
20%, are some of the most aggressive human cancers. This dissertation begins with our 
analysis of 127 pHGGs, including brainstem (BS) and non-brainstem (NBS) tumors, 
from 118 patients using next-generation sequencing technologies. Nearly one-third of 
BS-HGGs, also known as diffuse intrinsic pontine gliomas (DIPGs), harbored somatic 
heterozygous missense mutations in ACVR1, coding for a receptor serine-threonine 
kinase involved in bone morphogenetic protein (BMP) signaling. These alterations led to 
gain-of-function as evidenced by increased phosphorylation of downstream targets in 
primary astrocytes and zebrafish embryo ventralization. Whole-genome sequencing and 
RNASeq revealed that nearly half of our cohort contained structural variants. We 
identified recurrent gene fusions preserving the kinase domain of the neurotrophin family 
of receptor tyrosine kinases (NTRK) including three novel fusions and two fusions 
previously described in other tumor types. NTRK fusion genes were identified in 40% of 
infant (<3 years of age) NBS-HGGs, and 7% of pHGG overall. We also found that 
infants have significantly reduced mutation burdens when compared to pHGGs in older 
children, suggesting a small number of oncogenic mutations are required in infant 
tumors. These findings, coupled with the observation that infants have a better prognosis 
than non-infants, make infant NBS tumors a distinct subgroup of pHGG. NTRK gene 
fusions also occur in pediatric low-grade glioma (pLGG) and adult glioblastoma but are 
not as enriched as they are in infant NBS-HGG, and adult glioblastoma and non-infant 
pHGGs exhibit higher mutation rates than infant tumors. NTRK fusion genes are 
therefore gliomagenic drivers throughout various development settings; yet it appears as 
if gliomas driven by the same oncogenic lesion can vary in tumor phenotype as a function 
of contextual differences. With this in mind, we used genetically engineered mice with a 
NTRK gene fusion knock-in allele to generate HGG in vivo. Given that tumor is evident 
by early postnatal life (P5), this is, to our knowledge, the first report of a bona fide 
spontaneous pHGG model. The second part of this dissertation is the characterization of 
these tumors. 
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CHAPTER 1.    INTRODUCTION* 
 
 
Introductory Comments 
 
Cancer is unequivocally a genetic disease. That fact is so fundamental to our 
understanding that we oftentimes take it for granted. Indeed, it is difficult for us to even 
fathom a paradigm that predates our own. However, the history of cancer, or rather its 
written history, stretches as far back as 3000 BC with Ancient Egyptian descriptions of 
breast tumors. And since then, theories of cancer etiology have been just as varied as the 
cancer themselves; from explanations such as gods and humoral imbalance to more 
recent hypotheses including lymph and blastema theory[1]. The isolation of DNA in 
1869[2] did not immediately seem relevant to the study of cancer, and it would take until 
the mid-20th century for the inception of oncogene theory[3]. Since that time, cancer 
biology has become predicated upon genetic alterations leading to gain-and-loss-of-
function of proteins involved in every cellular function imaginable, from signaling 
cascades promoting cell survival and proliferation to DNA damage repair to epigenetic 
regulation. The combination of events leading to neoplasia are varied, perhaps 
innumerable. Yet regardless of its complexity, cancer is a disease of a singular process: 
perturbation conferring a selective advantage.      
 
The role of genetic alterations in cancer, both inherited and acquired, is an 
obvious one. What has become evident more recently is the idea that cancers arising in 
adults are different from those in children. There are common cases for adult oncologists, 
such as lung cancer, that are rare for pediatric physicians and vice versa[4]. True as that 
may be, for cancers that occur throughout life the histopathology is indistinguishable 
between adults and children. This in turn led to the thinking that similar histology was the 
result of similar underlying genetics; resulting in the thinking that children are “little 
adults.” Fast forward to the 21st century. We can comfortably assert, informed by decades 
of genetic and molecular analyses, that such thinking is decidedly wrong. That is not to 
say there is no overlap whatsoever. Adult and pediatric cancers are indeed related, but 
they are also distinct. One issue that remains unresolved is the idea that pediatric cancers 
arise from an underlying genetic susceptibility. Many believe that the only way children 
can acquire the necessary hits for tumor formation, given their reduced latency, is 
through germline mutations leading to cancer predisposition syndromes. After 
sequencing thousands of tumor/matched normal pairs, we are still uncertain whether this 
is indeed the case or not. Only a minority of children who develop cancer carry germline 
mutations in known susceptibility genes[5]. However, our understanding of protein 
coding sequences is far from comprehensive and that of the remaining 98% of the non-
coding genome is even less; so the functional consequence of the ever-expanding catalog 
of germline variants identified in pediatric cancer patients remains to be seen[6]. What 
 
____________________________ 
* Reprinted with permission. Diaz, A.K. and S.J. Baker, The genetic signatures of 
pediatric high-grade glioma: no longer a one-act play. Semin Radiat Oncol, 2014. 24(4): 
p. 240-7. 
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this data has also revealed is that generally speaking, pediatric cancers exhibit lower 
mutation burdens than cancers more commonly seen in adults. Interestingly, but not 
altogether surprising, malignancies with known associations with environmental 
mutagens, such as lung and colorectal cancers, have some of the highest mutation 
burdens evident[7]. But it is important to keep in mind that there also exists heterogeneity 
within a given tumor type. For example, pediatric high-grade gliomas, an aggressive 
brain tumor that will be the focus of this dissertation, range from some of the quietest 
cancer genomes to having a hypermutator phenotype[8-11]. 
 
The Genomic Era continues onward, but it has already yielded critical insight. 
The differences between pediatric and adult cancers highlight the central importance 
developmental context plays in pathogenesis. But rather than merely serving as a 
backdrop, developmental context is an active participant, from determining the cell 
populations involved to influencing what genes are expressed. Yes, there are common 
pathways dysregulated in various cancer types regardless of age. And this should come as 
no surprise given their roles in cellular processes such as cell survival and proliferation. 
Yet when we look a bit more closely, we begin to see differences emerge as targeted 
effectors tend to differ between adults and children. Moreover, in certain instances we see 
involvement of a particular pathway/mechanism in one age group that does not appear 
implicated in the other.           
 
The success of the Genomic Era goes without saying. We now have a much better 
idea of who the culprits are (genetic events) in tumor formation. Exactly how these 
alterations are contributing to cancer is now the imperative; because it is with this 
knowledge that we can then attempt to take advantage of them therapeutically. 
 
 
High-Grade Gliomas 
 
Experts predict that nearly 80,000 new cases of primary brain/central nervous 
system (CNS) tumors will be diagnosed in the United States in 2016; primary meaning 
disease originating in the brain/CNS compared to metastases. Those estimates also 
indicate that about one-third of these cases will be malignant[12]. Brain tumors present 
clinicians with unique challenges that differ from other cancers. For one, most deaths 
from brain tumors are the consequence of a growing mass encased within a confined 
space leading to increased intracranial pressure resulting in loss of brain function[13, 14]. 
Additionally, the blood-brain barrier, which works in keeping harmful substances outside 
of the CNS, works in keeping potentially efficacious chemotherapies out as well[15]. As 
a result, certain brain tumors remain some of the most lethal cancers. 
 
Pathologists formally diagnose these cases by how they appear through the 
microscope; specifically, by cell morphology and protein expression via 
immunohistochemistry (IHC). If a tumor exhibits features of astrocytes, 
oligodendrocytes, or both, then it is referred to as a glioma. The most commonly used 
scheme for grading gliomas is that developed by the World Health Organization (WHO). 
It is a I-IV scale with grade I denoting the most benign form of disease and grade IV (also 
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known as glioblastoma) being the most aggressive. Going from grade I to grade IV, 
tumors exhibit increased mitotic activity, nuclear atypia, and anaplasia. Gliomas graded 
III and IV are collectively known as high-grade gliomas (HGG) whereas grades I and II 
are regarded as low-grade gliomas (LGGs)[16].  
 
Given the morphology that defines gliomas, it is logical to assert that they arise 
from glial cells. But specifically which one/s? In short, the issue remains unresolved. 
Gliogenesis is a highly complex process that involves a number of different cell types 
including stem and progenitor cells as well as transit-amplifying populations and of 
course fully differentiated astrocytes and oligodendrocytes. And when we take a look at 
the experimental data, a number of these possess the capacity to transform, leading to 
glioma formation. Glia formation in utero follows neurogenesis and continues throughout 
post-natal development. Multipotent neural stem cells (NSCs) divide asymmetrically 
yielding neuronal progenitors, astrocytic progenitors, and oligodendrocyte precursor cells 
(OPCs), with each giving rise to its differentiated namesake progeny. NSC populations 
persist even into adulthood, populating the subventricular zone (SVZ) and dentate gyrus, 
specifically the subgranular zone[17]. Evidence supporting NSCs as a putative cell-of-
origin includes the ability of proliferative niches to generate gliomas in mice upon 
retroviral delivery of oncogenic mutations; whereas those same alterations failed to 
induce gliomagenesis outside of these niches[18-20]. Moreover, targeted depletion of 
cells expressing nestin (an intermediate filament and NSC marker) significantly impaired 
tumor growth in vivo[21]. As for the role of astrocytes in tumor initiation, numerous 
studies have been conducted taking genetically altered primary astrocyte cultures and 
implanting them into recipient mice with subsequent glioma formation[8, 22-29]. 
Spontaneous models have also implicated astrocytes; using an inducible expression 
system, researchers targeted Cre-mediated recombination in adult brains, specifically in 
cells expressing glial fibrillary acidic protein  (GFAP). And although the marker is 
expressed both in astrocytes and NSCs, nearly a quarter of the gliomas that formed did so 
outside of the SVZ and subgranular zone, with no evidence of disease originating in those 
areas. Albeit indirectly, what this demonstrates is an increased capacity of NSCs to 
transform relative to astrocytes but with astrocytes still possessing such potential[30]. 
Aside from the growing experimental literature supporting OPCs as glioma initiating 
cells[31], a particular gene expression signature associated with HGG, known as the 
proneural subtype, shows extensive overlap with OPCs[32]. This, coupled with the fact 
that OPCs actually outnumber NSCs in the adult brain[33-35], leads many to believe that 
at least a portion of HGGs arise from this cell population.          
 
Even prior to interrogation with microarrays or next-generation sequencing 
(NGS), it was reasonable to suspect that pediatric gliomas were different from those in 
adults. For one, the majority of adult gliomas are high-grade whereas in children, the 
most common gliomas are low-grade tumors. Also, where gliomas arise differs as a 
function of age: most gliomas in adults occur in the cerebral hemispheres while in 
children, a broader range of areas are affected. High-grade tumors of the brainstem are 
commonly referred to as diffuse intrinsic pontine gliomas (DIPGs). Brainstem HGGs 
almost exclusively occur in children, making it a uniquely pediatric disease, and roughly 
half of pediatric HGG cases are DIPGs[12, 36]. Another distinguishing feature between 
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adult and pediatric gliomas is the frequency of malignant transformation, the process 
where a patient presents with a high-grade tumor that was previously diagnosed as a 
lower grade[37]. Lastly, the current standard of chemotherapeutic care for adult high-
grade glioma, the alkylating agent temozolomide, has not been shown to improve 
survival in pediatric trials[38-40]. Collectively, these observations hinted at the 
possibility of pediatric HGG (pHGG) having a distinct genetic etiology from adult HGG 
(aHGG). 
 
 
The Genetics of Adult and Pediatric High-Grade Glioma  
 
 A great deal of work has gone into uncovering the genetics underlying HGG. 
During my time as a graduate student, I published a review that was intended to be a 
comparative analysis between the adult and pediatric forms of the disease. Quoted text in 
this section is taken from that review[41].  
 
Genetic studies of aHGG, specifically glioblastoma, revealed dysregulation in 
three main networks: the retinoblastoma (RB), p53, and receptor tyrosine kinase (RTK)-
Ras-phosphotidylinositide 3-kinase (PI3K) pathways[42-44]. “The p53 and RB pathways 
regulate G1 cell cycle checkpoints. Mitogenic signaling activates the cyclin D-dependent 
kinases CKD4 or CKD6, coupled with cyclin D family members (CCND1/2/3). This 
complex phosphorylates pRB, releasing E2F and promoting transcription of genes 
responsible for G1-S cell cycle progression. The tumor suppressor locus CDKN2A 
encodes 2 different proteins through translation of 2 different reading frames, p16INK4A 
and p19ARF. p16INK4A inhibits the activity of the cyclin D-dependent kinases CKD4 
and CKD6. Oncogenic signals, DNA damage, or induction of p19ARF induces p53, 
leading to cell cycle arrest, apoptosis, or senescence[45]. Mutations in the RTK-Ras-
PI3K pathway transduce unregulated signals for cell proliferation, growth, and survival. 
RTK signaling begins when growth factor ligand binding leads to receptor dimerization. 
Upon dimerization, RTKs trans-phosphorylate one another at tyrosine residues in their 
cytosolic tails. p85, the regulatory subunit of PI3K, can then either directly bind to these 
phosphorylated tyrosine residues or connect to RTKs through adaptor molecules and Ras. 
PI3K comprises catalytic (p110) and regulatory (p85) subunits (Figure 1-1)[46].  
 
As the genomic landscape of aHGG came into view, it shaped initial work into 
the pediatric disease. The first pHGG studies focused primarily on investigating the 
involvement of high-frequency recurrent events found in adult tumors. For example, 
epidermal growth factor receptor (EGFR) is the most commonly altered RTK in aHGG; 
with the corresponding gene locus undergoing amplification or intragenic deletion or 
both in ~50% of cases[42-44]. First identified in adult glioblastoma, EGFR variant III 
(EGFRvIII) is the most common EGFR variant in aHGG and is formed by deletion of 
exons 2-7 resulting in a constitutively active kinase[47-49]. Accordingly, investigators 
early on sought to examine the degree of EGFR involvement in pediatric cases of HGG.  
 
A number of studies found that EGFR alteration was less frequent in pHGG[50-
56], although gene amplification and EGFRvIII expression were detected in some   
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Figure 1-1. The p53, RB, and RTK-Ras-PI3K pathways are dysregulated in both 
adult and pediatric HGG.  
(A) The p53 and RB pathways regulate G1 cell cycle checkpoints. Mitogenic signaling 
leads to activation of the cyclin D-dependent kinases, CKD4 or CKD6, coupled with 
cyclin D family members, which confer substrate specificity. CDK4/6-Cyclin D 
complexes, in turn, phosphorylate pRB, facilitating E2F-mediated transcription of genes 
leading to G1-S cell cycle progression. Gene amplifications of CDK4, CDK6, or the 3 
cyclin D family members (CCND1/2/3) are found in pHGG, and moreso in DIPG. The 
tumor suppressor locus CDKN2A encodes 2 different proteins, p16INK4A and p19ARF. 
p16INK4A inhibits CDK4/6-Cyclin D complex activity. Oncogenic signals, DNA 
damage, or induction of p19ARF upregulates p53 expression, leading to cell cycle arrest, 
apoptosis, or senescence. Homozygous deletions of CDKN2A occur almost exclusively in 
pediatric NBS-HGGs, whereas TP53 mutations are common regardless of age or 
location. (B) RTK signaling initiates when growth factors bind, leading to 
receptor dimerization. In pHGG, PDGFRα is the most commonly targeted RTK, either by 
amplification or mutation or both. Upon dimerization, RTKs trans-phosphorylate one 
another at tyrosine residues in their cytosolic tails. These phosphorylated tyrosines can 
then either bind directly to p85, the regulatory subunit of PI3K, or bind PI3K indirectly 
through adaptor molecules and Ras. PI3K comprises catalytic (p110) and regulatory 
(p85) subunits, both of which are targeted by mutation, usually in a mutually exclusive 
pattern, in pHGG. pRB, RB protein. 
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pHGGs[57-60]. Through genome-wide studies, PDGFRA, which encodes platelet-
derived growth factor receptor alpha (PDGFRα), was identified as the most commonly 
targeted RTK in both DIPG and pediatric non-brainstem HGG (pNBS-HGG). Alterations 
in the gene itself include amplification, mutation, or both[24, 50-52, 55, 56, 60-63]. 
Experimentally, overexpression of wild-type (WT) or mutant PDGFRα confers a growth 
advantage to astrocytes, an effect that is diminished by the introduction of the adenosine 
triphosphate-competitive inhibitors crenolanib or dasatinib. PDGFRα mutants drive 
glioma formation in vivo[24, 25], with murine-derived HGGs recapitulating critical 
features of the human disease such as histopathologic characteristics and expression 
profiles[24]. In an effort to target PDGFR therapeutically, pediatric trials using dasatinib, 
crenolanib, or imatinib have been launched[64-66]. Unfortunately, the benefit derived 
from selective RTK inhibitors may be marginal at best. pHGGs show evidence of 
intratumoral heterogeneity, with some cells co-amplifying multiple RTK genes or 
discrete cell populations within the same tumor amplifying different genes, suggesting 
that resistant populations are likely to be present even before treatment with targeted 
agents[51, 61].  
 
Both PDGFRA and EGFR are part of the RTK-Ras-PI3K signaling cascade, 
which is altered in nearly 90% of aHGGs. Additionally, ~80%-90% of adult tumors show 
evidence of RB and p53 pathway dysregulation[42-44, 67]. For this reason, many of the 
first genetic pHGG studies focused on these same networks.  
 
In adults, the most commonly targeted components of the RTK-Ras-PI3K axis 
downstream of RTKs include activation of PI3K itself, or loss of function of phosphatase 
and tensin homolog (PTEN), the main negative regulator of PI3K signaling, or NF1, a 
negative regulator of Ras-mediated signaling[42-44]. Activation of PI3K signaling 
caused by mutations of PIK3CA, encoding the catalytic p110α subunit of PI3K, or 
PIK3R1, encoding the regulatory subunit of PI3K, is usually present in mutually 
exclusive patterns, occurring in approximately 20% of aHGGs and in a similar frequency 
of pHGG, including DIPG[8-11, 42, 62, 68-72]. The PTEN tumor suppressor is located 
on chromosome 10q. It remains unclear whether all tumors with loss of chromosome 10q 
are targeting PTEN loss of function when a WT PTEN allele is still retained. However, 
there are examples in experimental systems where PTEN haploinsufficiency contributes 
to tumorigenesis. Loss of heterozygosity (LOH) of chromosome 10q, with or without 
concurrent PTEN mutation, is very frequent in adult glioblastoma, with 10q LOH in 
approximately 80% and PTEN mutation in 25%-40%, whereas the frequency is 
significantly lower in pHGGs, with 10q LOH in approximately 30% and PTEN mutation 
in less than 5%-15%[8, 42, 50-53, 55, 56, 60-63, 69, 73-75]. 
 
RB pathway dysregulation is common in both pNBS-HGGs and DIPG. The 
CDKN2A locus codes for 2 tumor suppressors, p16INK4a and ARF[45]. Notably, 
homozygous deletion of CDKN2A/B appears to be almost exclusive to pNBS tumors and 
largely absent in DIPGs[50-52, 55, 56, 60-63, 76]. In contrast, amplification of CDK4/6 
or CCND1/2/3 is found in approximately 30% of DIPG[51, 55, 61]. Therapeutic 
inhibition of this cyclin-CDK complex, using PD-0332991, a highly-selective non– 
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adenosine triphosphate–competitive CDK4/6 inhibitor, significantly increased survival in 
a murine model of DIPG, both as a single agent or following irradiation[77].  
 
TP53 mutations occur in up to 35% of pNBS-HGGs (range: 18%-35%) and 
appear to be more common in DIPGs (40%- 50% of cases)[8-11, 54, 62, 67, 69, 73-75, 
78, 79].  
From the aforementioned data, we can conclude that although the 3 main 
signaling pathways affected in aHGG are also affected in pHGG, pediatric and adult 
tumors differ regarding the most frequently mutated effectors.  
 
Despite some common copy number imbalances such as 13q and 14q loss in 
approximately one-third of patients with HGG regardless of age or location, aHGG and 
pHGG also exhibit a unique constellation of gains and losses that distinguish one from 
the other, and the same can be said for DIPGs and pNBS-HGGs[50-52, 55, 56, 60-63]. 
This suggests that unique combinations of genetic drivers underlie adult and pediatric 
tumorigenesis, and among childhood HGG, DIPG and pNBS-HGG tumorigenesis.  
 
Transcriptional analysis of tumors supports similar conclusions. Clustering of 
gene expression signatures from aHGGs identifies 3-4 major gene expression subgroups, 
with the most robust distinction between proneural and mesenchymal subgroups[32, 80-
82]. Unlike the WNT and sonic hedgehog subgroups of medulloblastoma (another type of 
pediatric brain tumor)[83], the mutations associated with particular HGG subgroups are 
much less consistent. These same subgroups were identified in pHGGs by unsupervised 
comparisons, showing a clear relationship in the gene expression signatures of gliomas 
among different age groups and locations. However, supervised comparisons revealed 
expression signatures that distinguished adult from pediatric tumors, and within 
childhood glioma, DIPGs from pNBS-HGGs[51, 52, 55, 61, 84, 85].  
 
Because biopsy on patients with DIPG is not routinely performed in the United 
States, most research material is acquired at autopsy from irradiated patients. The vast 
majority of these samples are designated grade IV[86]. In contrast, clinicians in France 
regularly perform pretreatment biopsies, and although most samples were HGGs, some 
were classified as low grade[87], raising the possibility that there may be a low-grade to 
high-grade malignant transformation in the genesis of DIPG. Importantly, there is a high 
degree of similarity in the copy number imbalances and expression signatures from 
DIPGs collected as biopsy samples before treatment and those collected at autopsy, 
which were treated by radiation in most cases, with or without chemotherapy[51, 61]. 
Furthermore, expression signatures of pediatric brainstem LGGs are much more closely 
related to non-brainstem LGG and not to DIPGs, emphasizing a different etiology 
underlying genesis of LGG and HGG arising in the brainstem[51].  
 
This body of work established the concept that oncogenic events driving pediatric 
HGG were different from those arising in adults. This appreciation, however, was not 
fully cemented until early 2012, with the discovery of recurrent histone mutations in 
pHGG (Figure 1-2). As the first reports of histone mutations in human cancer, these  
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Figure 1-2. Hot-spot histone mutations occur in nearly 80% of DIPGs and ~35% 
of NBS-HGGs.  
(A) The basic unit of chromatin is the nucleosome, in which the DNA is wrapped around 
a histone octamer consisting of 2 copies of H2A, H2B, H3, and H4. The N-terminal tails 
of histones undergo post-translational modifications (PTMs), represented by yellow and 
blue circles, which in turn alter chromatin accessibility and recruitment of effector 
proteins, together influencing transcriptional permissiveness. This is accomplished 
because PTMs can (1) themselves alter the strength of DNA-histone interactions and (2) 
facilitate recruitment of chromatin remodeling complexes or histone PTM-binding 
effector proteins. (B) p.K27M substitutions occur in histone H3.1 and H3.3; p.G34R/V 
substitutions occur in H3.3. Histone H3.1/3.3 p.K27M exerts a dominant effect, 
preventing the accumulation of H3K27me2/3 on the wild-type histone H3 expressed in 
the same cell. p.G34R/V mutations do not exert the same effect on H3K27me3, but 
p.K27M and p.G34R/V histone mutations are associated with distinct genome-wide DNA 
methylation and gene expression tumor signatures. (C) Table summarizing the functional 
consequences of histone mutations. 
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publications implicated novel mechanisms in pHGG tumor biology that are not found to 
play a significant role in the adult disease.  
 
Whole-genome sequencing of 7 DIPGs and matched germline DNA, as part of the 
St. Jude Children's Research Hospital-Washington University Pediatric Cancer Genome 
Project, identified somatic mutations in H3F3A leading to a p.K27M substitution in 
histone H3.3 in 4 of 7 cases. A fifth case contained an analogous mutation in HIST1H3B 
yielding a p. K27M alteration in histone H3.1. Subsequent targeted sequencing of all 15 
genes encoding histone H3 in a larger cohort of pHGG found p.K27M somatic mutations 
in 78% of DIPGs: 60% were mutations in H3F3A and 18% in HIST1H3B[88]. Similar 
frequency of histone H3 mutation was found in an independent cohort; however, the 
proportion of H3F3A and HIST1H3B mutations varied between the groups, likely owing 
to patient age, with HIST1H3B mutations arising in younger children[88, 89]. In pNBS-
HGG, H3F3A and HIST1H3B p.K27M substitutions were found in 19% and 3% of cases, 
respectively. Additionally, 14% of pNBS-HGGs harbored somatic mutations in H3F3A 
leading to p.G34R substitution, whereas no such alteration was identified in any DIPG. 
Most of the DIPG samples evaluated were collected at autopsy. However, of 8 DIPG 
samples collected from patients who had not received adjuvant therapy, 7 contained 
p.K27M substitutions. Hence, histone H3 alterations were not necessarily secondary to 
therapy[88].  
 
Collaborating groups in Canada and Germany performed whole-exome 
sequencing of 48 pNBS-HGGs and identified p.K27M, p.G34R, and p.G34V alterations 
in 19%, 10%, and 2% of cases, respectively, with all changes affecting H3F3A encoding 
the histone H3.3 variant. Additional targeted sequencing of the H3F3A locus in more 
than 700 samples of gliomas of various grades from patients of different ages revealed 
these mutations to be exclusive to high-grade tumors and significantly enriched in 
pediatric cases. Of the 11 adult cases harboring H3F3A mutation, all were missense 
substitutions of G34, and the majority were identified in young adults aged 20-30 years. 
The specific histone mutation was associated with anatomical location. p.K27M 
mutations occurred in tumors involving midline structures (such as the brainstem, 
cerebellum, and thalamus), whereas p.G34R/V mutations occurred in non-midline 
supratentorial lesions (Figure 1-3) [8, 69].  
 
Nucleosomes are the basic unit of chromatin, in which DNA is wrapped around a 
nucleosome core composed of a histone octamer with 2 copies each of histones H2A, 
H2B, H3, and H4. H3F3A and HIST1H3B code for the 2 histone H3 variant isoforms 
H3.3 and H3.1, respectively. There are 3 isoforms of histone H3. Histone H3.1 and H3.2 
are encoded by 10 and 3 separate genes, respectively, and are synthesized during S phase 
of the cell cycle to package newly replicated DNA. Histone H3.3 is synthesized 
throughout the cell cycle and selectively incorporated into promoter regions of active 
genes, and through interactions with ATRX (alpha thalassemia/mental retardation 
syndrome X-linked) and DAXX (death domain-associated protein 6), into peri-
centromeric heterochromatin and sub-telomeric regions[90]. Notably, recurrent ATRX 
loss-of-function mutations were found in approximately one-quarter of pHGG, which 
were also associated with alternative lengthening of telomeres. All tumors with H3F3A  
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Figure 1-3. Histone mutations are strongly associated with anatomical location.  
Midsagittal (A) and coronal (B) magnetic resonance images demonstrate that p.K27M 
mutations occur predominantly in tumors involving midline structures (the brainstem, 
cerebellum, and thalamus), whereas p.G34R/V mutations mainly occur in tumors arising 
in the cerebral hemispheres.  
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 p.G34R/V mutation carried concomitant ATRX mutations, suggesting synergy between 
the 2 mutations[69].  
 
All identified histone mutations occur in the N-terminal tails of histones, 
unstructured regions that undergo extensive post-translational modification. These 
modifications in turn facilitate recruitment of effector proteins that regulate 
transcriptionally active or silent chromatin states[91]. 
 
All histone H3 mutations in pHGG were heterozygous, and in any individual 
tumor, only 1 of 15 genes encoding histone H3 was mutated. This pattern clearly 
indicates a dominant gain-of-function effect.  
 
Advances in microarrays and next-generation sequencing technologies have 
provided unprecedented insight into pHGG biology. These studies, both large and small 
scale, genome-wide and targeted, have given today's researchers and clinicians a better 
understanding of pHGG than ever before.” 
 
Closing Introductory Remarks 
 
 One hurdle shared by all researchers in studying pHGG is the relative lack of 
available biomaterial, with only several hundred new cases diagnosed in the United 
States each year[12]. This dissertation begins with the analysis of a cohort of 127 tumors 
by next-generation sequencing. The next chapter is the publication that resulted from 
those efforts with the subsequent chapter being an extension of one of the main findings 
from that report. 
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CHAPTER 2.    THE GENOMIC LANDSCAPE OF DIFFUSE INTRINSIC 
PONTINE GLIOMA AND PEDIATRIC NON-BRAINSTEM HIGH-GRADE 
GLIOMA* 
 
 
 The second chapter of this dissertation will be the publication that resulted from 
our analysis of 127 pHGGs, both DIPGs and NBS-HGGs[8]. Quoted text is taken from 
the manuscript. This study was a collaborative effort between our laboratory and Dr. 
Jinghui Zhang’s group in the Department of Computational Biology. I shared first 
authorship with Dr. Gang Wu who spearheaded the bioinformatic analysis of sequence 
data. My contribution was the functional study of the two primary genetic alterations 
described below.    
 
 “Although childhood and adult HGGs share related histopathological 
characteristics, adult HGGs arise predominantly in the cerebral cortex, whereas childhood 
HGGs more frequently involve a broader spectrum of locations. There are also 
substantial differences in the molecular features of pediatric and adult HGGs[43, 44, 50-
52, 55, 56, 61, 63, 69, 84, 92]. Histone H3 gene (H3F3A andHIST1H3B) mutations 
encoding p.Lys27Met are frequent in DIPGs, which arise in the brainstem almost 
exclusively in children, and in pediatric HGGs in midline structures such as the thalamus 
and cerebellum, whereas histone H3 gene mutations encoding p.Gly34Arg or p.Gly34Val 
occur in pediatric HGGs of the cerebral cortex[69, 88, 89, 93]. In contrast, histone H3 
gene mutations are extremely rare in adult HGGs[69]. HGGs arising in infants younger 
than 3 years of age have a better prognosis and a lower frequency of TP53 mutations, 
suggesting that there may be age-dependent subgroups of HGG, even within the pediatric 
population[94]. Thus, the selective pressures driving gliomagenesis in children vary with 
age and anatomical site. 
 
To more comprehensively understand the pathways driving childhood glioma, we 
analyzed the genomic landscape of HGGs from 118 pediatric cases (127 tumors, 108 
matched to germline DNA) consisting of 57 DIPGs and 70 NBS-HGGs by whole-
genome (n = 42), whole-exome (n = 80) and transcriptome (n = 75) sequencing. A total 
of 39,590 sequence mutations, including single-nucleotide variations (SNVs) and small 
insertions or deletions (indels), and 2,039 structural variations were found by whole-
genome sequencing, and an additional 2,600 sequence mutations and 138 structural 
variations were found by exome sequencing and transcriptome sequencing, respectively. 
Overall, the cohort showed a median background mutation rate of 9 x 10−7 mutations per 
base and a median of 22 structural variations per genome. All SNVs and structural 
variations found by whole-genome sequencing were verified experimentally by 
independent sequencing methods. 
 
____________________________ 
* Reprinted with permission. Wu, G., Diaz, A.K., et al., The genomic landscape of diffuse 
intrinsic pontine glioma and pediatric non-brainstem high-grade glioma. Nat Genet, 
2014. 46(5): p. 444-50.   
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Among recurrent mutations in pediatric HGG, the most frequently mutated gene 
not previously identified in cancer was ACVR1 (also known as ALK2) encoding a bone 
morphogenetic protein (BMP) type I receptor (Figures 2-1 and 2-2). Clonal 
missense ACVR1 mutations were found exclusively in DIPGs (32%) and were 
significantly associated with younger age, longer survival time and the presence 
of HIST1H3B mutation encoding p.Lys27Met (P < 0.0000001) or 
with PIK3CA or PIK3R1 mutations (P < 0.005) (Figures 2-1 and 2-2). Four of these 
somatic ACVR1 mutations were the same as germline mutations previously identified in 
the autosomal dominant syndrome fibrodysplasia ossificans progressiva (FOP), in which 
aberrant cellular differentiation drives progressive heterotopic ossifications[95, 96]. All 
residues affected by mutation in DIPGs clustered around either the inhibitory glycine-
serine-rich (GS) domain or the ATP-binding pocket of the kinase domain and would be 
expected to shift the kinase to an active conformation (Figure 2-2)[97]. Indeed, 
mutations affecting these residues induced a weak gain of function[97, 98]. A previous 
study showed that the ACVR1 mutation encoding p.Arg206His caused a ventralized 
phenotype in zebrafish embryos, an indicator of BMP pathway activation[99]. We tested 
all of the ACVR1 mutations found in DIPG using this assay. Zebrafish embryos injected 
with wild-type human ACVR1 mRNA displayed a mild dorsalized phenotype consistent 
with BMP pathway inhibition, whereas injection with mRNA for all six ACVR1 mutants 
resulted in varying degrees of ventralization, with partial to complete loss of head and 
dorsal structures (Figure 2-2b, c). A moderate dose of LDN-193189, a highly selective 
antagonist of the BMP pathway[99, 100], partially reversed the ventralization effects 
induced by ACVR1 mutants, as demonstrated by the rescue of dorsal head structures for 
the Arg258Gly, Gly328Glu, Gly328Trp and Arg206His mutants and the reduced severity 
of ventralization for the Gly356Asp and Gly328Val mutants (Figure 2-2c). Expression of 
ACVR1 mutants in mouse primary astrocyte cultures caused increased levels of 
phosphorylated SMAD1 and SMAD5 (SMAD1/5), a downstream indication of active 
BMP signaling, with varying magnitude (Figure 2-2d). LDN-193189 also effectively 
blocked signaling to phosphorylated SMAD1/5 downstream of mutant ACVR1 in 
primary astrocytes. 
 
Recurrent and clonal activating mutation of ACVR1 in 32% of DIPGs provides 
strong evidence that ACVR1 is an oncogenic driver in this disease. However, 
germline ACVR1 mutation in the genetic syndrome FOP is not associated with cancer 
predisposition, indicating that ACVR1 mutation likely provides a selective advantage in 
the presence of other critical mutations rather than driving tumor initiation. Consistent 
with this hypothesis, all six of the DIPG-associated ACVR1 mutants failed to 
render Tp53-null mouse astrocytes tumorigenic when implanted into the brain (data not 
shown). BMP signaling is associated with contrasting effects dependent on context, 
driving astrocytic differentiation or the proliferation of early hindbrain progenitors[101]. 
In tumors, BMP signaling induced the differentiation of medulloblastoma[102] but drove 
either a differentiation or proliferation response in glioblastoma stem cells, related in part 
to the epigenetic state of the cell[103, 104]. These context-dependent consequences likely 
drive the exclusive association between ACVR1 mutation and DIPG. 
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Figure 2-1. Recurrent genetic alterations in pediatric HGG.  
Genetic alterations detected in 19 genes, including ACVR1 and the genes most recurrently 
mutated in the pathways indicated on the left, are displayed. A diagonal white line 
indicates loss of the wild-type allele or a male case for ATRX, which is X linked. H3F3A 
(H3.3) and HIST1H3B (H3.1) mutations are grouped together in the category histone H3. 
Structural variants involving NTRK1, NTRK2 or NTRK3 and copy number variants 
(CNVs) of components of the CCND1, CCND2, CCND3, CDK4 or CDK6 G1 checkpoint 
complex are grouped together. Tumor subgroup (DIPG or NBS-HGG), location of NBS-
HGG (midline versus cerebral hemisphere) and World Health Organization (WHO) 
tumor grade are indicated. White boxes for location or tumor grade indicate information 
not available. Mutations for 112 HGGs are shown. Four hypermutator samples and 11 
samples for which only RNA-seq data were available were excluded from this summary. 
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Figure 2-2. ACVR1 mutations in DIPG activate BMP signaling.  
(A) Missense ACVR1 substitutions in DIPG were clustered in the GS or kinase domains. 
Each red circle indicates a DIPG carrying the specified alteration, and an asterisk 
indicates alterations previously found as germline mutations in individuals with FOP. The 
extracellular domain (EC) and transmembrane domain (TM) were not affected by 
mutations. (B) Human ACVR1 mutants ventralize zebrafish embryos. The graph shows 
the percentage of embryos exhibiting a dorsalized or ventralized phenotype. Embryos 
injected with wild-type ACVR1 mRNA (WT) showed a dorsalized phenotype, whereas 
embryos injected with mutant ACVR1 mRNA showed a ventralized phenotype 
(increasing severity from left to right). The Arg258Gly mutant had the least severe effect, 
resulting only in the V3–V4 ventralized phenotype, whereas the Gly328Val mutant had 
the most severe effect, with 90% of embryos showing the V5 ventralized phenotype. The 
number of embryos examined is shown on top. (C) Representative phenotype images of 
zebrafish embryos injected with the indicated ACVR1 mRNA. Untreated embryos 
expressing the Arg258Gly, Gly328Glu, Gly328Trp and Arg206His mutants have few to 
no dorsal structures, and embryos expressing the Gly356Asp and Gly328Val mutants are 
more severely affected. Treatment with LDN- 193189 reversed the ventralization effects 
of mutant ACVR1, as demonstrated by the partial rescue of dorsal structures (e.g., the 
head) in embryos expressing the Arg258Gly (100%, n = 20), Gly328Asp (83%, n = 23), 
Gly328Trp (100%, n = 20) and Arg206His (100%, n = 27) mutants and the reduced 
severity of ventralization showing a decrease in the proportion of embryos with the V5 
phenotype without the formation of dorsal structures for embryos expressing the 
Gly356Asp (89%, n = 27) and Gly328Val (49%, n = 24) mutants. Scale bar, 200 µm. (D) 
ACVR1 mutations drive increased levels of phosphorylated SMAD1/5 (pSMAD1/5) in 
primary astrocyte cultures. Protein blots are shown for lysates of primary astrocytes 
isolated from the brainstem of neonatal mice with conditional knockout of Tp53 
transduced with retroviruses expressing Flag-tagged wild-type ACVR1 or the indicated 
mutants and serum starved for 2 h. Quantification of the ratio of phosphorylated SMAD 
to total SMAD normalized to the empty vector control is shown below. 
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Principal-component analysis using the 1,000 most variable probe sets showed 
that HGG samples clustered by tumor location with no segregation of DIPGs 
by ACVR1 mutation status. Genes involved in the regulation of immune system processes 
showed significantly different expression in DIPGs with and without ACVR1 mutation 
(Fisher's exact test, P = 0.0002, false discovery rate (FDR) = 0.26%). 
 
Structural variants generating fusion genes were common and were identified in 
47% of pediatric HGGs, in equal proportions of DIPGs and NBS-HGGs, from 
transcriptome and whole-genome sequencing data. Gene fusions involving the kinase 
domain of each of the three neurotrophin receptor (NTRK) genes and five different N-
terminal fusion partners were identified in 4% of DIPGs and 10% of NBS-HGGs. 
Notably, 40% (4/10) of NBS-HGGs in children younger than 3 years old contained 
an NTRK fusion gene (Figures 2-1 and 2-3). The NTRK receptors transduce a wide range 
of developmental signals in the nervous system, including the induction of neurite 
outgrowth, differentiation and neuronal survival or death[105, 106]. NTRK fusion genes 
have recently been identified at low frequency in low-grade pediatric astrocytomas as 
well as in adult glioblastomas[107-109]. Two of the five NTRK fusions found in our 
cohort, TPM3-NTRK1 and ETV6-NTRK3, were previously identified in other cancer types 
and shown to be oncogenic[110-114]. 
 
To test the ability of NTRK fusion genes to drive glioma formation, we 
implanted Tp53-null primary mouse astrocytes transduced with retrovirus expressing 
Flag-tagged human TPM3-NTRK1 or BTBD1-NTRK3 into mouse brain. Both NTRK 
fusions induced high-grade astrocytomas with very short latency and complete 
penetrance (Figure 2-3b). The resulting tumors showed elevated levels of 
phosphorylated AKT and p42/44 mitogen-activated protein kinase (MAPK), downstream 
indicators of phosphoinositide 3-kinase (PI3K) and MAPK pathway activation. 
 
Although NTRK-activating fusions were specifically found at high frequency in 
tumors from infants, activation of receptor tyrosine kinase (RTK)-RAS-PI3K signaling 
through other mutations was frequent across the entire cohort, occurring in 69% of 
DIPGs and 67% of NBS-HGGs (Figure 2-1). In contrast to previous reports detecting 
EGFRvIII expression in pediatric HGG[58, 59], we only detected EGFRvIII expression 
in 1 of the 85 tumors analyzed by whole-genome sequencing or RNA sequencing (RNA-
seq). 
 
In addition to recurrent histone H3 gene, ATRX and SETD2 mutations reported 
previously[69, 88, 89, 93, 115], we also detected frequent mutations of other histone 
writers and erasers and of chromatin-remodeling genes (Figure 2-4). Interestingly, 
mutations affecting histone H3 writers were significantly more frequent in NBS-HGGs 
(P = 0.007), whereas frequencies of mutations affecting histone erasers were not 
significantly different in DIPGs and NBS-HGGs (P = 0.3). Although 
only ATRX mutations were highly recurrent, collectively, this group of genes involved in 
epigenetic regulation was targeted by mutation in 22% of DIPGs and 48% of NBS-
HGGs, excluding histone H3 gene mutations (Figure 2-4). These mutations were often 
concurrent with missense mutations in histone H3 genes. Indeed, including histone H3  
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Figure 2-3. Three structural variants generate oncogenic chimeric NTRK fusion 
proteins.  
(A) All fusions included the C-terminal kinase domain from NTRK1, NTRK2 or NTRK3 
(blue). N-terminal fusion partners include the tropomyosin domain (yellow) of TPM3, an 
actin-binding protein fused to NTRK1, and the BTB/POZ dimerization domain (gray) 
and the Kelch domain (orange) from the topoisomerase I–interacting protein BTBD1 or 
the pointed protein-protein interaction domain (purple) of the ETS transcription factor 
ETV6 fused to NTRK3. The N terminus of the actin-binding protein vinculin (light blue; 
VCL) was fused to NTRK2, and the N terminus of the ATP/ GTP-binding protein 
AGBL4 (green) was fused to NTRK2. The functional carboxypeptidase domain of 
AGBL4 is not present in the fusion protein. For each fusion protein, the dashed red line 
shows the fusion point, with the amino acid positions of the N-terminal and C-terminal 
fusion partners at the breakpoint indicated. The number of amino acids in each full-length 
fusion protein is shown at the lower right of each fusion. (B) NTRK fusion proteins 
induce high-grade astrocytomas. Tp53-null mouse primary astrocytes isolated from 
neonatal cortex or brainstem were transduced with virus expressing Flag-tagged TPM3-
NTRK1 (top) or BTBD1-NTRK3 (bottom) and implanted into mouse brain. 
Representative hematoxylin and eosin staining (of seven independent mice per construct) 
shows pleomorphic tumor cells, many with features of astrocytic differentiation and high 
mitotic activity. Tumors induced by BTBD1-NTRK3 showed the frequent presence of 
giant cells reminiscent of giant cell glioblastoma. Immunohistochemical analysis showed 
expression of Flag-tagged NTRK fusion proteins and elevated levels of phosphorylated 
AKT (pAKT) and 44/p42 MAPK (p-44/p42 MAPK) in tumor relative to surrounding 
normal tissue. Scale bar, 50 µm.  
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Figure 2-4. Pediatric HGG alterations in histone modifiers or chromatin 
regulators.  
Alterations identified in NBS-HGG or DIPG are shown. Genetic alterations were 
identified in proteins that attach (writers; above) or remove (erasers; below) post-
translational modifications of lysine residues (Lys4, Lys9, Lys18, Lys27, Lys36) in the 
tail of histone H3, as well as proteins involved in modifications of other histones or 
chromatin remodelers. Notably, there were no alterations in writers or erasers of Lys27, 
which is directly mutated at high frequency in DIPG and, to a lesser degree, in NBS-
HGG. Ub, ubiquitination; ac, acetylation; ph, phosphorylation; H2, histone H2; H4, 
histone H4. 
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gene mutations, 91% of DIPGs, 70% of midline NBS-HGGs and 48% of hemispheric 
NBS-HGGs contained mutations in histone genes and/or this subgroup of epigenetic 
regulators. p.Lys27Met histone H3.3 or H3.1 alteration results in a dominant loss of tri-
methylation at lysine 27 of histone H3 (H3K27me3) in the entire cellular pool of histone 
H3 proteins[116-119]. Mutations that modulate H3K27me3 levels by targeting 
components of the Polycomb-repressive complex 2 (PRC2) that methylates H3K27 or the 
H3K27 demethylases KDM6A and KDM6B are found in other tumor types[120-125]. 
However, there were no such mutations across the entire HGG cohort, including in 
DIPGs with wild-type histone H3 genes, supporting the unique selective advantage of 
p.Lys27Met alteration in pediatric HGG (Figure 2-4). Mutations in transcriptional 
regulators that affect the epigenetic landscape were also found, including focal 
amplifications of MYC and MYCN, which encode transcription factors that act to amplify 
the levels of expressed genes across the genome[126, 127], and truncating mutations in 
the transcriptional corepressor genes BCOR andBCORL1 (Figure 2-1). 
 
There was an enormous range in the complexity of the somatic mutations driving 
pediatric HGG. The ten NBS-HGGs in children under 3 years old showed significantly 
lower mutation rates than the rest of the cohort (P < 0.0001), suggesting that only a small 
number of driver mutations is required in tumors from this age group (Figures 2-5 and  
2-6). ETV6-NTRK3 fusion was identified as one of only two non-silent alterations in 
SJHGG082, a glioblastoma from a 1-month-old subject. Notably, NTRK fusion genes, 
including two of the fusions found here, have been identified in multiple tumor types, 
including those from very young children such as congenital fibrosarcoma, as well as in 
papillary thyroid cancer, an adult disease[108, 110, 112-114]. The high frequency 
of NTRK fusion genes in NBS-HGGs from children younger than 3 years of age, the 
paucity of additional mutations in these tumors and the rapid tumor onset in our 
experimental glioma model strongly suggest that these fusion genes are potent oncogenic 
drivers in early postnatal brain tumor development. 
 
Four tumors, 3 with matched normal DNA, were scored as hypermutators, with an 
extremely high background mutation rate, including more than 800,000 somatic 
mutations in SJHGG111 in which biallelic germline PMS2 mutations were identified 
(Figure 2-6). Subject SJHGG003 carried a heterozygous germline PMS2 mutation and 
developed a grade IV hemispheric malignant glioneuronal tumor (MGNT) and a separate 
DIPG. Although both tumors independently acquired different somatic inactivating 
mutations in the remaining PMS2 allele, the basal mutation rate in the first tumor arising 
in this case, the MGNT (SJHGG003_D), was nearly 100-fold higher than in the DIPG 
that arose 2 years later (SJHGG003_A), demonstrating the potential range in the tumor 
mutation burden associated with inherited mutation in DNA mismatch repair genes 
(Figures 2-5 and 2-6). Hypermutator tumors were excluded from the evaluation of 
mutation frequency. Seven cases carried germline mutations in known cancer 
predisposition genes, including TP53, PMS2, MSH6 and NF1. 
 
Thirteen tumors (31%) analyzed by whole-genome sequencing had 
chromothripsis[128], identified by complex rearrangements with multiple interconnecting 
breakpoints corresponding to genomic segments with oscillating copy number states  
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Figure 2-5. Circos plots showing the range of structural alterations in pediatric 
HGG. 
Circos plots display the genome by chromosome in a circular plot and depict structural 
genetic variants, including DNA CNAs, intra- and interchromosomal translocations, and 
non-sequence mutations. Orange, loss of heterozygosity (LOH); red, amplification; blue, 
deletion. Sequence mutations in RefSeq genes: brown, missense SNV; red, indel; blue, 
splice-site SNV. Genes at structural variation breakpoints: pink, gene involved in in-
frame fusions; blue, others. Subject SJHGG003 carried a germline PMS2 mutation and 
developed two independent tumors, first a hemispheric malignant glioneuronal tumor 
(SJHGG003_D) and, 2 years later, a DIPG (SJHGG003_A). The SNVs and indels for 
these two tumors were too numerous to include. The hypermutator tumor with more than 
800,000 somatic mutations had an extremely stable genome (SJHGG003_D), whereas the 
second tumor with approximately 100-fold fewer SNVs carried typical genomic copy 
number and structural abnormalities seen in other HGGs (SJHGG003_A), thus 
demonstrating the broad range and complexity of mutations associated with germline 
PMS2 mutation. SJHGG016_D is an infant NBS-HGG with a TPM3-NTRK1 fusion and a 
very stable genome. SJHGG027_D is an NBS-HGG from a case with A-T, showing a 
relatively stable genome. This tumor sample was collected before radiotherapy. 
SJHGG004_D is a DIPG with chromothripsis driving BTBD1-NTRK3 fusion. 
SJHGG044_D is an NBS-HGG showing dramatic chromothripsis. For the examples of 
chromothripsis, the names of the genes disrupted by structural variants were too 
numerous to display. 
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Figure 2-6. Outlier analysis of the tier1 mutation rate in all pediatric HGGs.  
Least median squares was used to find the narrowest interval containing at least 50% of 
the samples (shown in yellow) in terms of their tier1 mutation rate. An approximate 95% 
prediction interval was determined by modeling this interval as the inter-quartile range of 
a normal distribution (shown by the gray box). Only samples with matched germline 
DNA were used for this analysis. The mutation rate is significantly lower in tumors from 
children less than 3 years of age than in the others (p = 0.0005823, Wilcoxon rank-sum 
test), with NBS-HGG tumors from children less than three shown in blue and DIPGs 
from children less than 3 years of age shown in turquoise. Germline mutations are shown 
in red, with specific mutated genes labeled. Hypermutator samples were associated with 
germline PMS2 mutations and outlier mutation rates were also seen in samples with 
germline MSH6 or PMS2 mutation. In contrast, TP53 germline mutations show a range of 
mutation rates, including an outlier for low mutation rate. Germline ATM mutation was 
associated with a lower mutation rate than the narrowest bulk. A tumor from a patient 
with germline NF1 mutation fell within the narrowest bulk. 
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(Figure 2-5). In our cohort, chromothripsis resulted in oncogenic rearrangement, 
including BTBD1-NTRK3 fusion and rearrangement or amplification of 
PDGFRA and EGFR. Nearly half of all samples showing chromothripsis were collected 
before adjuvant therapy, indicating that the mechanism underlying their occurrence was, 
at least in some cases, independent of DNA-damaging therapeutics. SJHGG027_D, an 
NBS-HGG arising in a child with ataxia telangiectasia (A-T), had a relatively stable 
genome, despite a compromised DNA damage checkpoint due to the absence of 
functional ATM, ataxia telangiectasia mutated (Figures 2-5 and 2-6). Multiple sub-
clones were identified in almost all HGG tumors. A founder clone or a descendant of a 
founder clone in the diagnosis tumor could seed the development of relapsed or autopsy 
tumor. 
 
We identified TERT promoter mutations in only 2% of DIPGs and 3% of NBS-
HGGs, in strong contrast to the frequency of 86% identified in adult primary 
glioblastomas[129]. 
 
The genomic landscape of pediatric HGGs also includes frequent mutations in 
common cancer pathways, consistent with previous reports[50-52, 55, 56, 61, 63, 
69]. TP53 mutations occurred in 42% of pediatric HGGs and were mutually exclusive 
with truncating mutations in the TP53-induced phosphatase PPM1D, previously shown to 
impair the TP53-dependent G1 cell cycle checkpoint (Figure 2-1)[130]. The G1 
checkpoint regulators CCND1, CCND2, CCND3, CDK4 and CDK6 were predominantly 
amplified in DIPGs, whereas CDKN2A homozygous deletion was restricted to NBS-
HGGs (Figure 2-1). Taken together, mutations affecting cell cycle regulation, including 
the TP53 and RB pathways, were found in 59% of pediatric HGG (Figure 2-1). 
 
This global view of the genetic landscape of pediatric HGG defines critical 
pathways driving a devastating spectrum of childhood brain tumors and identifies high-
frequency mutations in potential therapeutic targets - ACVR1 in DIPGs and NTRK fusions 
in NBS-HGGs in infants.”  
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CHAPTER 3.    FUSIONS INVOLVING THE NEUROTROPHIN FAMILY OF 
RECEPTOR TYROSINE KINASES IN GLIOMAGENESIS 
 
 
Neurotrophin Signaling 
 
 As mentioned previously, NTRK gene fusions appear to be oncogenic drivers in 
multiple glioma types, both in adult and pediatric HGGs as well as pLGGs[8, 107-109], 
and the genetic landscape of these tumors can differ markedly. pLGGs resemble infant 
NBS-HGGs in having quiet genomes whereas adult glioblastoma and non-infant pediatric 
HGGs exhibit higher mutation burdens[8-11, 107-109]. Such differences also extend into 
the prognosis of these gliomas, further emphasizing the heterogeneity among them. For 
adult and non-infant HGGs, the two-year survival rate is <30%[36, 40]. By contrast, 
nearly 90% of children with LGG are alive a decade after diagnosis[131]. Although 
infants with NBS-HGG do fare better than non-infants, the clinical course of these 
patients is not akin to those with LGG[132], thereby debunking the idea that perhaps 
infant HGGs are diagnosed erroneously as high-grade or that they are merely low-grade 
tumors with high-grade histology.   
 
 The history of neurotrophin research is rich, dating back to the mid-20th century 
and includes the seminal work of Rita Levi-Montalcini and Stanley Cohen. In 1986, they 
were both awarded the Nobel Prize in Physiology and Medicine for the isolation of nerve 
growth factor (NGF)[133, 134]. In addition to NGF, the neurotrophin family of growth 
factors includes three other members: brain-derived neurotrophic factor (BDNF), 
neurotrophin-3 (NT-3), and neurotrophin-4 (NT-4). Collectively, these ligands and their 
cognate receptors (the Trk RTKs as well as the structurally unrelated p75NTR) are critical 
in the development of the nervous system. The consequences of neurotrophin signaling 
are diverse; mediating cell survival, differentiation, synaptic plasticity, and dendritic 
arborization as well as other cellular responses[135].  
 
 Neurotrophins are synthesized in the endoplasmic reticulum (ER) as precursors 
(proneurotrophins) with an N-terminal prodomain. Proteolytic cleavage of this domain 
either in the Golgi or secretory vesicles or extracellularly yields the mature ligand[136]. 
Existing as homodimers, mature neurotrophins can bind two different classes of cell 
surface receptors, the Trks or p75NTR. The former consists of three structurally related 
members (TrkA, TrkB, TrkC), while p75NTR is part of the tumor necrosis factor receptor 
(TNFR) superfamily. While both receptor types can bind mature ligand, p75NTR can 
additionally associate with proneurotrophins[137].  
 
 A common feature of the four neurotrophin gene loci is the existence of multiple 
5’ exons with the most 3’ exon containing the open reading frame for the 
proneurotrophin. Alternative splicing to include or remove certain 5’ exons leads to 
multiple mRNA transcripts, each with a distinct promoter. In fact, BDNF mRNA has 
been shown to be regulated by eight different promoters. Further transcriptional control is 
achieved by virtue of the fact that all but one neurotrophin gene, NGF, contain alternative 
polyadenylation sequences. And yet an additional level of complexity is seen for BDNF; 
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with a natural antisense transcript which can form a duplex with the coding strand, 
leading to RNA degradation. Although the role of these various transcripts remains to be 
seen, collectively they highlight the necessity of highly intricate gene expression for the 
development and maintenance of a functional nervous system[138].  
 
 Mature neurotrophins bind to Trk receptors. Alternative splicing of the sequence 
corresponding to the extracellular domains of all three NTRK genes alters the affinity 
each receptor has to the various ligands. Trk-neurotrophin coupling mediates receptor 
dimerization and subsequent trans-autophosphorylation of tyrosine residues. These 
phospho-tyrosines in turn activate three pathways associated with neurotrophins: the 
PI3K, MAPK, and phospholipase C gamma (PLCγ) networks (Figure 3-1). PI3K and 
MAPK signaling is initiated via the same residue whereas PLCγ activation occurs 
through a different phospho-tyrosine. PI3K can bind directly to phospho-tyrosine by its 
p85 regulatory subunit or through an adaptor complex including Shc, Grb2, and Gab1. 
The catalytic portion of PI3K, p110, then converts phosphatidylinositol 4,5-bisphosphate 
(PIP2) to phosphatidylinositol (3,4,5)-trisphosphate (PIP3), with the product serving as a 
docking site for pleckstrin homology (PH) domain-containing proteins, such as AKT. 
Full enzymatic activity of AKT is achieved through dual-phosphorylation at T308 and 
S473. At the same phospho-tyrosine responsible for PI3K activity, MAPK pathway 
signaling initiates with recruitment of Grb2 and SOS. A guanine nucleotide exchange 
factor, SOS then activates Ras and subsequently leads to downstream MAPK activation 
via phosphorylation of both threonine and tyrosine within a conserved TEY motif of the 
kinase domain. Together, both MAPK and PI3K converge on transducing signals for cell 
survival, proliferation, growth, and protein synthesis. A direct binding site for PLCγ on 
Trk is generated when the most C-terminal tyrosine of the receptor is phosphorylated. Trk 
phosphorylation of PLCγ-1 Y783 is both necessary and sufficient to induce enzyme 
activity. The expression of a second PLCγ isozyme, PLCγ-2, is restricted to immune 
cells. Both PLCγ and PI3K are similar in that they alter member lipid composition by 
acting on the same substrate. PLCγ hydrolyzes PIP2 yielding the second messengers 
inositol trisphosphate (IP3) and diacylglycerol (DAG). Whereas the former facilitates 
Ca2+ release from the ER, DAG remains membrane-bound and promotes protein kinase C 
(PKC) signaling. Neurotrophin-Trk complexes are then internalized by clathrin-mediated 
endocytosis and can be recycled back to the membrane or degraded. Collectively, this 
process is known as canonical Trk signaling. Research has also identified two non-
canonical Trk pathways: 1) neurotrophin-independent activation and 2) signaling via 
truncated isoforms lacking a kinase domain. However, the biological importance of these 
remains to be seen[139]. 
 
 An enigma of sorts early during its study, p75NTR  is another type of neurotrophin 
receptor. Much of the confusion was initially due to the ability of p75NTR to mediate both 
apoptotic and survival signaling. It has since been shown that these outcomes are highly 
context-dependent and rely on the receptor’s ability to bind both proneurotrophins as well 
as mature ligand and also on its ability to form complexes either with Trk or with the 
type-1 receptor sortilin. Structurally, the intracellular domain lacks enzymatic activity 
and serves as a scaffold for adaptor recruitment[140].   
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Figure 3-1. The NTRK signaling pathway.  
(A) Dimers of four ligands (NGF, BDNF, NT-3, NT-4) bind with varying affinity to the 
three NTRK receptors (TrkA, TrkB, TrkC). Upon neurotrophin binding, Trk receptors 
trans-phosphorylate at specific tyrosine residues. Phosphorylation of a C-terminal 
tyrosine leads to activation of PLCγ. When a more N-terminal tyrosine is phosphorylated, 
it results in activation of both MAPK and PI3K. (B) PI3K activation can occur through 
direct binding of p85, the regulatory subunit of PI3K, to Trk receptors. Alternatively, p85 
can bind indirectly through its association with adaptor molecules and Ras. The catalytic 
p110 component of PI3K alters membrane lipid composition by converting PIP2 to PIP3, 
with the latter resulting in AKT activation. Ras can also initiate the MAPK signaling 
cascade. Both pathways transduce signals critical for cell survival, proliferation, growth, 
and protein synthesis. (C) Similarly to PI3K, PLCγ alters membrane composition by 
acting on PIP2 to generate the second messengers IP3 and DAG. The former facilitates 
Ca2+ release from the ER whereas the latter induces the activity of PKC.  
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 Discovery of the first Trk receptor occurred when a novel gene fusion was 
identified in colorectal cancer. Genomic rearrangement combined the N-terminal 
sequence of TPM3, a tropomyosin gene, with a C-terminal sequence corresponding to the 
kinase domain of a previously unidentified RTK[141]. Named for its fusion partner, 
tropomyosin receptor kinase A, or TrkA as it would later be known, was the founding 
member of a family comprising two other such molecules. That initial report was 
published in 1986. Since then, additional NTRK fusion genes have been described across 
multitude cancer types (in both adult and childhood malignancies within and outside the 
CNS) with varying frequency (ranging from 0.2%-100%)[142]. And although those 
numbers may change as larger cohorts are studied and detection methods become 
increasingly sensitive, the fact remains that NTRK gene fusions drive tumorigenesis in 
numerous cancer contexts.         
 
 We have recently analyzed 127 patient samples, both DIPGs and NBS-HGGs, 
through whole-genome sequencing, whole-exome sequencing, and transcriptome 
sequencing. Our efforts revealed that 40% of infant NBS-HGGs contain NTRK fusion 
genes, and these were found in 7% of pHGGs overall. When ranked by tier 1 mutation 
rate, infant tumors clustered together as having significantly quieter cancer genomes when 
compared to non-infants[8]. These findings, coupled with the observation that infants have 
a better prognosis than older children, suggests that infant NBS tumors are a distinct 
subgroup within pHGG[36, 132]. Although less frequent, NTRK fusion genes also occur 
in pLGG (nearly 4%)[107, 108] and adult glioblastoma (1%)[109]. Genomically, infant 
HGG resembles pLGG in exhibiting few mutations whereas adult glioblastomas appear 
more somatically altered both in terms of copy number alterations and SNVs. Thus NTRK 
gene fusions are gliomagenic drivers throughout various development settings; yet it 
appears as if gliomas driven by the same oncogene can vary in tumor phenotype as a 
function of contextual differences. I hypothesize that the molecular heterogeneity of 
NTRK-driven gliomas stems from a dynamic vulnerability to oncogenic events 
inherent to developmental context. 
 
Methods 
 
Implant studies 
 
 Tumorigenesis implant studies were done as previously described[23]. Briefly, 
hGFAP-cre[143] and Trp53loxP/loxP[144] mice were crossed to drive homozygous Tp53 
deletion. Primary astrocyte cultures were established from postnatal day 2 (P2) pups. 
Murine stem cell virus (MSCV) retroviral vectors were used to introduce expression of 
C-terminally FLAG-tagged NTRK fusions. The MSCV vector contained an IRES-
mCherry fluorescent reporter. Transduction efficiency was obtained by flow analysis to 
determine the percentage of cells expressing mCherry. Transduced astrocytes were 
subsequently implanted into the brain of athymic recipient mice.  
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Mouse dissection 
 
Animals requiring dissection were given 1mL Avertin (12.5mg/mL) IP. Mice 
subsequently underwent thoracotomy and after puncture of the atria, were perfused with 
PBS. Harvested brain tissue was subsequently placed in 4% PFA and whenever possible, 
additional snap frozen material was collected. Tails were collected to confirm initial 
genotyping results. 
 
 
Mouse modeling 
 
 Mouse modeling was based on the Etv6-NTRK3 genetically engineered mouse 
model previously generated for the study of breast cancer in the lab of Dr. Stuart Orkin 
[114]. Briefly, the human NTRK3 cDNA sequence encoding the kinase domain was 
inserted into exon 6 of one of the murine Etv6 alleles. A lox-stop-lox cassette was placed 
immediately upstream from the cDNA sequence yielding a conditional knock-in allele. 
Tp53loxP/loxP mice[144] were also used to generate heterozygous and homozygous floxed 
alleles. Cre-mediated recombination was achieved using the transgenic nestin-cre (NCre) 
line, which utilizes enhancer and promoter elements of rat origin[145]. NCre has 
widespread expression of recombinase in the CNS beginning midway through 
embryogenesis (E10.5). We additionally utilized Rosa26-stop-EYFP mice as a reporter 
for Cre activity. In this line, the sequence encoding enhanced yellow fluorescent protein 
gene (EYFP) was inserted into the Rosa26 locus with an upstream lox-stop-lox 
sequence[146]. Expression of YFP will therefore be limited to cells in which Cre is 
active.     
 
 
Immunohistochemistry/Immunofluorescence  
 
 Harvested brain tissue was placed in 4% PFA in 1x PBS for 24h. Samples were 
then processed and embedded in paraffin. Sectioning of tissue was done at a thickness of 
5 microns. Slides to be stained were deparaffinized and rehydrated. Slides were placed in 
citric acid (pH = 6) and heated until boiling for antigen retrieval. Endogenous peroxidase 
was quenched by placing slides in 0.6% H2O2 for 30 minutes. For blocking of non-
specific binding sites, slides were incubated in 10% goat serum in TBS-T (0.01% Tween-
20 in TBS) for 1h. Afterwards, blocking solution was removed and primary antibody was 
diluted in 2% goat serum in TBS-T, with slides left to incubate overnight at 4°C. For the 
second day of staining, slides were incubated with the species-appropriate biotinylated 
secondary antibody in 2% goat serum in TBS-T for 1h at room temperature. Since 
secondary antibodies were biotinylated, signal amplification occurred though avidin-
biotin complexing for 30m at room temperature (Vector Laboratories, catalog number: 
PK-6100). NovaRed (Vector Laboratories, catalog number: SK-4800) and DAB (Vector 
Laboratories, catalog number: SK-4100) were the substrates utilized. Slides were then 
counter-stained, dehydrated, and coverslipped. Antibodies used: anti-FLAG (Sigma-
Aldrich, F1804), anti-pPLCγ1 T783 (Cell Signaling Technology, 14008), anti-pAKT 
S473 (Cell Signaling Technology, 9271), anti-p-p42/44 MAPK Thr202/Tyr204 (Cell 
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Signaling Technology, 4370), anti-Ki67 (Novocastra, NCL-Ki67p), anti-Olig2 
(Millipore, MABN50), and anti-Sox2 (Millipore, AB5603).            
 
 
Results 
 
NTRK fusion genes were found in 40% of infant NBS-HGG and in 7% of our 
overall pHGG cohort. Interestingly, one of the fusion genes, ETV6-NTRK3, has been 
described in other pediatric neoplasms such as congenital fibrosarcoma and congenital 
mesoblastic nephroma[147-149]. So to test the ability of ETV6-NTRK3 to drive glioma 
formation in vivo, we conducted an implantation study. Cortical astrocytes were 
harvested from hGFAP-cre;Tp53loxP/loxP P2 pups and primary cultures were established. 
Astrocytes were transduced with either an empty vector MSCV construct or one coding 
for ETV6-NTRK3, both with a mCherry fluorescent reporter. Transduction efficiency was 
1.5%-2% for ETV6-NTRK3 based on flow analysis. 2x106 cells were implanted into the 
cortex of CD-1 nude mice. Animals injected with astrocytes expressing ETV6-NTRK3 
had a median survival of 36 days (Figure 3-2). The tumors from these mice were 
formally diagnosed as HGG and show evidence of MAPK and PLCγ activity by IHC 
analysis. Fusion protein expression was confirmed by IHC detection of a C-terminally 
engineered FLAG tag (Figure 3-2). 
 
 In addition to our pHGG cohort, NTRK fusion genes have been found in pLGG 
and adult glioblastoma[107-109]; meaning the same driver promotes tumor formation in 
diverse contexts. This prompted us to examine how oncogenic potential changes as a 
function of developmental setting. To this end, we utilized genetically engineered mouse 
models. Subsequent experiments utilized three such models described in the “Methods” 
section of this chapter: Etv6-NTRK3 (EN3) knock-in, Nestin-cre (NCre), and Tp53loxP/loxP 
mice. We initially crossed heterozygous EN3 males to hemizygous NCre females to 
generate offspring that were positive for both alleles. Brainstem and cortical primary 
astrocyte cultures were established from P2 pups. A cell viability assay (XTT) was 
performed which showed an increase in cells expressing the fusion gene compared to 
controls (Figure 3-3). Expression of EN3 was confirmed by RT-PCR. Mice were bred to 
include Rosa26-stop-EYFP so that Cre activity could be determined. Over 90% of cells 
were YFP-positive by flow analysis.  
 
In addition to mice with WT Tp53, we bred in Tp53 floxed alleles to generate 
NCre;EN3;Tp53+/- and NCre;EN3;Tp53-/- progeny. Tumor development was 
incompletely penetrant with WT Tp53, at least by gross examination. Five mice exhibited 
neurological symptoms and had tumor development that was apparent during dissection. 
Seven had to be euthanized due to unrelated health issues, such a paraphimosis or rectal 
prolapse, but one of these had evidence of tumor upon histological review. Seven mice 
were euthanized or died without neurological abnormality and did not have gross 
evidence of disease. Analysis of NCre;EN3 mice remains ongoing and paraffin-
embedded tissue will need to be sectioned and evaluated microscopically. We were taken 
aback at the rate of tumor development in NCre;EN3;Tp53-/- mice, with a median 
survival of 18 days (Figure 3-4). The median survival of NCre;EN3;Tp53+/- mice was 58  
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Figure 3-2. Astrocytes expressing ETV6-NTRK3 generate HGG when implanted 
into recipient mice.  
Tp53-null astrocytes were transduced with retrovirus encoding ETV6-NTRK3 with a C-
terminal FLAG tag. Cells were subsequently implanted into the cortex of 
immunocompromised mice. (A) Kaplan-Meier comparing mice injected with astrocytes 
transduced with ETV6-NTRK3 or empty vector retrovirus. (B) ETV6-NTRK3 drives 
HGG formation with activation of MAPK and PLCγ. 20x H&E and IHC sections using 
antibodies targeting the indicated epitopes.  
 
 
  
 32 
 
 
Figure 3-3. Expression of EN3 confers a proliferative advantage in vitro.  
XTT from brainstem and cortical primary astrocytes harvested from NCre and NCre;EN3 
P2 pups. Findings consistent throughout all three replicates.    
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Figure 3-4. Kaplan-Meier curve of five cohorts: NCre;EN3;Trp53-/- (red), 
NCre;EN3;Trp53+/- (black), NCre;EN3 (purple), NCre;Trp53-/- (blue), and 
NCre;Trp53+/- (green).  
Five NCre;EN3 mice had neurological symptoms with evident tumor during dissection. 
Seven NCre;EN3 animals were euthanized due to unrelated health issues; one tumor upon 
histological review. Seven NCre;EN3 mice were euthanized or died without neurological 
abnormality and did not have gross evidence of disease. Analysis of the NCre;EN3 cohort 
remains ongoing.  
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days. Tumors in NCre;EN3;Tp53-/- mice were diagnosed formally as HGG, exhibiting a 
high-proliferative index (by Ki-67), infiltration of normal parenchyma, and satellitosis 
(Figure 3-5). Tumors were analyzed by IHC to detect pAKT-S473 and p-p42/44 MAPK 
Thr202/Tyr204, which is consistent with activation of PI3K and MAPK, respectively 
(Figure 3-6).  
 
Given the rapid onset, we were interested to see earlier stages of tumorigenesis in 
NCre;EN3;Tp53-/- mice. We therefore examined the brains of P5 pups. Even by this time 
point there was high-grade disease (Figure 3-7). To see if EN3 was driving 
gliomagenesis in a tumor stem-cell-like population we performed immunofluorescence to 
detect Olig2 and Sox2. P5 tumors were largely comprised of discrete cell populations of 
either Olig2-positive or Sox2-positive cells. A very small minority of double-labeled cells 
were found and these appeared near tumor edges (Figure 3-7). As previously mentioned, 
NTRK signaling involves three pathways. In order to dissect the contribution each has on 
tumor formation, we needed to establish tumor cell lines. Tumorspheres were generated 
from three different NCre;EN3;Tp53-/- HGGs. To confirm that cultured cells were indeed 
tumor (and not immortalized NSCs given their Tp53-null status), we implanted 250,000 
cells into the cortex of immunodeficient mice. All injected mice developed HGG (Figure 
3-8), indicating successful establishment of in vitro renewable models of the 
NCre;EN3;Trp53-/- HGGs.           
 
 
Discussion 
 
To say ETV6-NTRK3 is a potent oncogenic driver would be an understatement. 
Despite a transduction efficiency of 1.5%-2%, this fusion gene was able to generate 
HGGs with a shorter latency than similar experiments with the majority of cells 
expressing various PDGFRA mutants. But this was merely the beginning, as the mouse-
human chimera of this same fusion protein was able to generate the first spontaneous 
pediatric model of HGG. This is far and away the most significant aspect of this work. 
For one, it provides a new platform for pre-clinical study. Our current approach to 
analyzing potential therapeutic agents includes in vivo testing using an implantation 
model. However, these experiments are in adult immunocompromised mice. The tumor 
latency of NCre;EN3;Tp53-/- mice (median, 18 days) allows us to administer a compound 
to not only see if the agent works, but to also ascertain the toxicology profile during a 
physiologically relevant pediatric setting. 
 
 Our analysis continues. We collected snap frozen tissue and have since submitted 
this for RNASeq in the hopes of identifying the downstream targets that render this 
fusion gene so transforming. The EN3 knock-in model was initially developed for the 
study of breast cancer. In that context, researchers discovered that the fusion protein’s 
oncogenicity was through activation of the AP1 transcriptional complex. AP1 itself is a 
dimeric complex comprised of members from the Jun, Fos, Maf, and ATF families. It 
will be interesting to see if EN3-driven gliomagenesis acts similarly or engages another 
downstream effector. Additionally, we will now look prenatally to uncover the initial 
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Figure 3-5. NCre;EN3;Trp53-/- mice generate HGG.  
(A) Sagittal H&E section of a P18 tumor-bearing mouse showing extent of disease 
burden. (B) 10x H&E and Ki-67 sections demonstrate a high proliferative index. (C-F) 
40x H&E. Native neurons are highlighted by arrows; mitotic figures are highlighted by 
circles. (C) Moderate to severe cytologic pleomorphism, including some multinucleated 
giant cells. (D) Infiltration of normal tissue by astrocytoma cells. (E) Mitotic figure. (F) 
Tumor cells demonstrate some satellitosis around cortical neurons and a mitotic figure.  
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Figure 3-6. Tumors from NCre;EN3;Trp53-/- mice show activation of PI3K and 
MAPK.  
20x H&E and IHC sections using antibodies targeting the indicated epitopes.   
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Figure 3-7. NCre;EN3;Trp53-/- mice have high-grade disease by P5.  
(A) Sagittal H&E section of a P5 mouse with evidence of HGG. (B) 20x H&E section 
demonstrating sub-pial growth of infiltrating astrocytoma and involvement of the 
Virchow-Robin spaces. (C-E) 40x H&E. Native neurons are highlighted by arrows; 
mitotic figures are highlighted by circles. (C, E) Sections demonstrating infiltrating 
astrocytoma with mitotic activity. (D) Section demonstrating infiltrating astrocytoma 
with perivascular growth pattern. (F) 20x immunofluorescence of tumor and adjacent 
normal with triple labeling of DAPI, Sox2, and Olig2. Image taken to show tumor 
involvement of Virchow-Robin space. Tumor consists largely of two discrete 
populations: singly labeled Olig2 or Sox2 positive cells. The few double positive cells 
appear in tumor edges.   
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Figure 3-8. Tumorspheres from NCre;EN3;Trp53-/- mice generate HGGs when 
implantated into recipient mice.  
Tumorsphere cell lines were established from a NCre;EN3;Trp53-/- tumor-bearing mouse 
that was euthanized at P21. At passage 2, 250,000 cells were injected into the cortex of 
immunocompromised mice. (A) All recipient mice were euthanized 26 days post-
injection due to moribund status. (B) Sagittal H&E sections demonstrate that implant-
derived HGGs recapitulate features of the parental spontaneous tumor.   
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stages of tumorigenesis; to see how expression of ETV6-NTRK3 affects native cell 
populations during the beginning of the gliogenic window.  
 
We are hopeful this model and these studies will yield insight into how these 
tumors develop. Currently in the pHGG research community, phrases such as “unique 
selective pressures” and “developmental context” form the backbone of our manuscript 
introductions and discussions. They are essentially fancy descriptors of the black box that 
is HGG formation in children. Perhaps now we can start to shed some light on this 
process, giving our words a bit more meaning.    
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CHAPTER 4.    DISCUSSION 
 
 
ACVR1 
 
ACVR1 mutations are somatic heterozygous missense alterations, with the 
remaining WT allele intact. Even without considering any functional data, this pattern is 
suggestive of gain-of-function; making mutant ACVR1 an oncogene. 
  
The identification of ACVR1 mutations in DIPG was similar to the discovery of 
histone mutations in that they both implicated novel biology in disease pathogenesis. 
Although showing dysregulation in the 3 core pathways of HGG, prior genetic and 
molecular studies had never found a role for BMP signaling. 
  
BMPs belong to the transforming growth factor beta (TGFβ) superfamily along 
with activins. They bind membrane receptors known as type II receptors. Two type II 
receptors then bind two type I receptors, which ACVR1 is, forming a tetrameric complex. 
When this occurs, type II receptors phosphorylate ACVR1 in a GS rich regulatory 
domain. In the unstimulated state, this region forms a docking site for FKBP12, rendering 
the kinase of the type I receptor inactive. Phosphorylation of this GS domain causes 
FKBP12 to dissociate, allowing ACVR1 to phosphorylate its targets, the receptor-
regulated SMADs 1/5/8 (R-SMADs). A trimer is then formed consisting of two R-
SMADs and common-mediator SMAD4 (co-SMAD). This trimer subsequently 
translocates to the nucleus and mediates expression of downstream targets including the 
inhibitor of DNA-binding/differentiation (Id) family of transcription factors. Non-
canonical BMP signaling is SMAD independent and leads to activation of p38 
MAPK[150]. 
  
As previously mentioned, our group and others have shown that ACVR1 
mutations render its kinase domain constitutively active. Recently, two publications have 
uncovered an additional function: the ability of mutant ACVR1 to signal upon binding of 
a traditional BMP antagonist, activin A[151, 152]. Normally, activin A transduces signals 
along the TGFβ axis while simultaneously preventing BMP activation by binding 
ACVR2A and ACVR2B, the type II receptors known to couple with ACVR1[150]. As a 
result, when mutant ACVR1 is present, the pathway will be active whether or not ligand 
is present and when inhibitor is present as well. 
  
The p.K27 position of histone H3.1 and H3.3 can undergo mono-, di-, and tri-
methylation as well as acetylation, and these modifications are carried out by a number of 
enzymes[90, 91, 120]. p.K27M mutations lead to a global loss of histone H3 K27 tri-
methylation, despite the mutant protein being a minority of the total cellular fraction of 
histone H3[116-118]. After sequencing of our cohort, we were surprised to learn that the 
evolutionary pressure in pHGG is specific for selecting p.K27M to reduce tri-
methylation, to the exclusion of possible alterations to the modification machinery 
affecting that amino acid[8]. Similarly, the tumor dynamics within DIPG target the BMP 
pathway solely through mutant ACVR1, conferring a selective advantage specific to the 
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brainstem given these mutations are restricted to this area[8-11]. It is for these reasons, in 
addition to frequency, that both these alterations are appealing therapeutic targets. These 
tumors have selected very specific paths for achieving particular functional outcomes, 
with no evidence of alternative mechanisms. That is not to say one would not emerge in 
the face of targeted therapy. In fact, that is to be expected given how aggressive these 
cancers are. For RTKs, resistant populations are already present even prior to any 
proposed targeted agent; we see the same tumor targeting multiple RTKs either in the 
same cell or in different subclones[51]. However, it seems that resistance would have to 
be acquired in the case of ACVR1 and histone H3. Even if only transiently effective, 
such treatments may add a month or two months to overall survival, which are 
meaningful steps we need to take in order to reach our goal of a cure.  
  
In individuals with FOP, mesenchymal stem cells aberrantly differentiate to 
osteoblasts[95]. Knowing activin A mediates BMP signaling through mutant ACVR1 
helps us to understand why heterotopic ossification is exacerbated by tissue injury. 
Activin A is a known mediator of inflammation and works in antagonizing the BMP 
pathway. However, mutant ACVR1’s capacity to phosphorylate R-SMADs upon activin 
A binding transforms an environment that typically restricts the expansion of bone-
forming cells into one that promotes it. So is there an inflammatory component to HGGs? 
Certainly; microglia can be seen in and around tumors and a hallmark of grade IV tumors 
is necrosis. But these features are shared by all HGGs, regardless of age and location. It is 
worth mentioning that we found BMP activation regardless of ACVR1 status, with no 
appreciable difference in levels of phospho-SMAD 1/5 between mutant and WT 
tumors[8]. Perhaps then all pHGGs rely on BMP signaling. More pronounced 
inflammation may exist in certain tumors, initially suppressing pathway activity. But 
once ACVR1 is mutated, the inflammatory milieu switches to promote BMP signaling. 
This possibility is supported by the fact that an inflammatory expression signature 
significantly associates with ACVR1 mutation[8]. 
  
Can restriction of ACVR1 mutation to the brainstem provide insight to a potential 
cell of origin? BMP activation in NSCs promotes astrogliogenesis and prevents 
oligodendrocyte differentiation[153]. Given no increase in cancer incidence in FOP 
patients, we believe ACVR1 is playing a role in tumor progression rather than initiation. 
Imagine then a scenario where a tumor in the brainstem is growing, causing local 
inflammation. The microenvironment is now rich in cytokines and other molecules, 
including activin A. A hypothetical cancer stem cell, a transformed NSC, acquires 
an ACVR1 mutation that, rather than promoting terminal differentiation, leads to 
unchecked proliferation of a tumor transit amplifying astrocytic population. Several cell 
types have demonstrated gliomagenic potential, but perhaps the trajectory outlined above 
occurs in a subset of DIPGs, given the enrichment of ACVR1 mutations in younger 
patients. The pons itself is broken down into a ventral basis pontis and dorsal tegmentum, 
and DIPGs are thought to arise from the former. So what is in this area of the pons? 
Longitudinal and transverse fibers in addition to the pontine nuclei. There exists a 
Nestin+ cell population in the human ventral pons that is most prevalent shortly after 
birth. Interestingly, this cell type makes a resurgence in middle childhood, roughly 
corresponding to the ages of highest incidence for DIPG[154]. 
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NTRK Gene Fusions and Infant NBS-HGG 
 
To say we were taken aback at the oncogenic capacity of NTRK fusion genes 
would be an understatement. Despite an abysmal transduction efficiency of less than 2%, 
Tp53-null astrocytes transduced with an ETV6-NTRK3 retroviral construct managed to 
generate HGGs within a few weeks after implantation. And in our spontaneous model, 
when the mouse-human chimera of this same alteration is expressed with concomitant 
Tp53 deletion in embryonic NSCs, it was able to establish true pediatric disease.    
 
NTRK signaling involves three pathways: MAPK, PI3K, and PLCγ. Early 
investigations looking at NTRK focused on the contribution of the first two and 
understandably so, given their involvement in cancer. Site-directed mutagenesis of the 
tyrosine responsible for PLCγ activation did not abolish the ability of fusion genes to 
transform NIH3T3 cells[155], an immortalized line of mouse fibroblasts. However, that 
is not to say the pathway is not contributing. We see evidence that it is active in our 
systems, and part of the potency of NTRK fusion genes may very well stem from this 
axis. PLCγ converts PIP2 to the second messengers IP3 and DAG. The former is 
responsible for Ca2+ release from the ER while DAG remains membrane-bound and 
activates PKC[139]. The list of downstream targets of the various PKC isozymes is 
extensive. Yet those isozymes found to promote tumor formation have been linked to 
activation of both PI3K and MAPK, in addition to upregulation of cyclin D leading to 
pRb hyperphosphorylation[156]. Prolonged NTRK signaling leads to downregulation of 
its associated receptors, including at the level of expression[139]. These fusion genes are 
impervious to this type of regulation however as they are under the control of their N-
terminal partner; which, in addition to the activation of three pathways, could contribute 
to their oncogenic potential. We were intrigued to see that the NTRK fusion genes in our 
cohort were not highly expressed as is the case with most other oncogenes[8]. Perhaps 
this diminished susceptibility to transcriptional control circumvents the need for 
increased expression to overcome potential inhibition.      
 
Interestingly, the frequency of TP53 mutation is significantly less in infant NBS-
HGGs (10%) than it is in pHGG overall (55-70%)[7, 8]. Although we were able to 
generate a few tumors without deletion of the gene, NTRK-driven gliomagenesis required 
knockout of Tp53. The infant developmental context may require targeting of the 
pathway by other means, such as upregulation of the p53 negative regulator MDM2 or 
downregulation of the CDK inhibitor p21, itself a p53 effector. Given how barren these 
tumors are mutationally, dysregulation of the aforementioned targets, or any others, may 
occur at the epigenetic level rather than through genetic alteration. Then again, this 
particular developmental setting may not require direct perturbation.  
 
Acute lymphoblastic leukemia (ALL) is the most common pediatric malignancy. 
And like pHGG, a small subset of these occur in very young children. Known as infant 
ALL, these cancers typically arise within the first year of life. Similar to the enrichment 
of NTRK fusion genes in infant NBS-HGG, infant ALL exhibits characteristic 
rearrangements involving the mixed lineage leukemia (MLL) gene in a majority of cases 
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(~80%)[157]. Another similarity between these two diseases is the paucity of somatic 
mutations in their cancer genomes. But unlike the youngest pHGG patients who have a 
better prognosis than older children, infants with ALL appear to have a particularly 
aggressive disease and fare worse than non-infants. So what could account for this? MLL 
is a methyltransferase responsible for histone post-translation modification, making it a 
global transcriptional regulator. It would therefore be reasonable to suspect that 
rearrangements leading to MLL fusions would involve its enzymatic SET domain, but 
this is not the case. These gene fusions result in epigenetic deregulation and disrupt 
transcription of target genes[157]. Any mutation that is selected for enhances 
evolutionary fitness. And while the same could be said for those leading to epigenetic 
dysregulation, there is a distinction between these alterations and others: widespread 
epigenetic deregulation perturbs numerous genes rather than just one. In infant ALL we 
see this whereas in infant NBS-HGG we do not, and this could potentially explain the 
difference in prognosis between the two.  
 
NTRK fusion genes drive HGG formation in a number of developmental settings: 
in NBS tumors both in infants and older children, DIPG, and adult glioblastoma, which 
arise predominantly in the cortex[8, 107-109]. A still unresolved issue in HGG biology is 
the identification of a putative cell of origin. In the previous section of this discussion I 
explored this subject as it pertains to DIPG. To summarize briefly, brainstem HGGs are 
thought to arise from the ventral pons. A nestin-expressing precursor cell exists in this 
area and is found to be at its highest numbers shortly after birth, slowly dwindling until 
about 2 years of age. This population subsequently increases around the same time that 
children typically are diagnosed with DIPG[154]. For adults, a legitimate case can be 
made for NSCs, OPCs, and astrocytic progenitors as these are actively proliferating. 
Various HGG models have been developed targeting genetic alterations in these cell 
types[158]. Others might be tempted to include neurons as a potential cell of origin, but 
arriving at such a conclusion would require a bit of mental gymnastics. Neurons are post-
mitotic, meaning that to be a HGG cell of origin, all necessary hits would have to occur 
in the same cell or robustly induce proliferation of a post-mitotic neuron to increase the 
likelihood of acquiring co-mutation of other critical genes. Possible? Yes, but unlikely.  
 
The issue is a bit more complex and nuanced when we look at infant and non-
infant HGGs outside the brainstem. In mice, gliogenesis begins by E15 and is largely 
complete by the first month of postnatal life. The pediatric brain is therefore abundant 
with mitotically active NSCs, OPCs, and astrocytic progenitors relative to the adult 
brain[17]. Our experimental systems demonstrate that P2 astrocytes, through 
implantation, and embryonically targeted NSCs have the capacity to generate HGGs. 
However, we must keep in mind that although genetic alterations are targeted in a 
specific cell type, it may be their more differentiated progeny that give rise to a 
tumor[159]. Aside from age, there are two key differences between infants and non-
infants with NBS-HGG that lead us to believe that they originate from different cell 
types: 1) the difference in prognosis and 2) the difference in mutation burden. Infants fare 
better than non-infants[132] and also have significantly quieter cancer genomes than 
older children[8]. So what then could account for this? In their “Hallmarks of Cancer,” 
Robert Weinberg and Douglas Hanahan detail the attributes a cell gains in the 
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progression toward malignancy[160, 161]. To a certain extent, stem cells and cancer cells 
resemble one another. Meaning that on the path leading to cancer, stem cells have a head 
start so to speak and possess a number of these traits intrinsically. Maybe this ancestral 
cell is what gives rise to infant tumors; its quiet genome a reflection of the minimal steps 
needed to get disease. Maybe the cell of origin for older children falls more along the 
differentiated side of the spectrum; with its mutation burden a reflection of the need to 
acquire more requisite traits of transformation which it was originally lacking. This 
remains an active area of investigation. In addition to using a constitutively active Cre, 
we can use inducible forms, under the same and different promoters, to introduce Etv6-
NTRK3 in various cell types and ages to see: 1) how these alter a cell’s ability to be 
transformed, 2) if the difference is due to a change in the transcriptional program, 3) if 
the NTRK-associated pathways are equivalently contributing to that program, 4) if the 
program is unique to NTRK fusion genes or shared by RTKs in general (comparing to a 
different model in the lab using transgenic mutant PDGFRA), and 5) if the responsible 
pathways can be targeted therapeutically. We are excited about this model for a number 
of reasons. First and foremost, it provides us a unique platform to perform preclinical 
testing. No other system yet described, be it implantation or spontaneous, generates HGG 
in a pediatric timeframe. This minimal latency will also enable us to work backwards 
from endpoint disease, similar to our P5 analysis, to see just how the fusion gene is 
functioning and in which cell type, giving us an opportunity to see the multistep 
tumorigenesis process in vivo. Tumorsphere cell lines can be established as well. By 
treating these with inhibitors of the NTRK-associated pathways it will be possible to 
determine if a particular axis is responsible for the fusion gene’s transcriptional program, 
thereby revealing a potential therapeutic vulnerability.   
 
A rather puzzling topic is that of NTRK fusion-driven infant NBS-HGG and 
pLGG. Their histologies differ and so too do their prognoses, but they resemble one 
another in that they are both minimally somatically altered. As previously mentioned, the 
prognosis for infant NBS-HGG lies in-between that of older children with HGG and 
pLGG. So what are the features of pLGGs harboring NTRK fusions? First, it should be 
noted that we are talking about four cases discovered thus far[107, 108]. Actually, in our 
cohort of pHGG, we had 10 infant tumors and four of those had NTRK gene fusions[8]. 
So between the two, we are talking about 8 cases total. But the four pLGGs that have 
been identified are in children older than 3 years and with tumors in the cortex[107, 108]. 
Now for the hand-waving. One could see this age discrepancy and conclude that these 
tumors arise from a different cell of origin or from the same cell but in a different time 
point in development. But LGGs are, by definition, slow-growing. Let us entertain the 
idea that both these tumors started from the same cell type. So how then do we account 
for their differences? Perhaps those that progressed to high-grade acquired additional hits 
but at the epigenetic level. Our spontaneous model indicates that NTRK-driven 
tumorigenesis requires few cooperating events. And so we could literally be talking about 
an alteration or two being the difference in this very specific instance.  
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Closing Remarks 
 
 I was extremely fortunate to be a graduate student during a period of tremendous 
growth in our understanding of the pHGG landscape. In the last 4 plus years the power of 
unbiased interrogation via next-generation sequencing has given researchers the ability to 
peer into the genetics of these tumors at an unprecedented level. The result? The 
suspicions of yesterday are now the truths of today: pediatric and adult HGGs are related 
but distinct. And when we take a closer look at children with HGG, we begin to 
appreciate that even within this age group, there is a spectrum of disease. Our work and 
the work of others identifies previously undescribed oncogenic drivers in different 
subgroups of pHGG: histone p.K27M and ACVR1 mutations in DIPG, less frequent 
p.K27M and FGFR1 mutations in thalamic tumors, H3F3A p.G34R/V alterations in 
laterally-located cortical HGGs, and the enrichment of NTRK fusion genes in infant 
NBS-HGG. This spatiotemporal distribution of genetic drivers underscores the 
importance and the uniqueness of the selective pressures involved in pediatric 
gliomagenesis.  
 
 This process, the doctoral training process, can be a whirlwind sometimes; 
empowering you one day only to leave you exasperated the next. And this is a good 
thing. Feeling that happiness and frustration is affirmation that you care about what you 
do. As I transition back to medical school I do so with a sense of excitement; not only for 
my own personal sake but also because I do so in a new era of pHGG study. The 
community has done well in identifying the genetic events that drive these tumors. And 
although we can take pride in those efforts, our satisfaction is short-lived. The imperative 
now is to use this information to shape the next generation of clinical trials. So imagine 
the position I find myself in: to have contributed in the research that leads to the trials I 
may be involved with as a physician-scientist. I am humbly grateful, now and always. 
Thank you.       
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